Royal Biologics has osteogenic solutions to address consistency, handling, and delivery characteristics.
Bone marrow is a reliable source of Osteogenic cells without the morbidity of autograft harvesting.
Bone marrow alone has the potential to support bone healing as demonstrated in preclinical and clinical studies reported in published literature.
Bone marrow aspiration is a widely used technique and may be combined with certain bone repair products to aid in the osteogenesis of bone.
BMA in combination with Royal DBM has a positive and possibly synergistic effect on healing as has been observed in preclinical and clinical studies.
BMA is derived from a patient’s bone marrow. It contains a heterogenous mix of stem and progenitor cells, platelets and white blood cells, each making their own contribution to the healing process.
Stem cells can differentiate into many different types of cells. There are several types of stem cells including hematopoietic and mesenchymal. They vary in differentiation potential and the terminal cell type they can become.
Hematopoietic Stem Cells (HSC’s) typically differentiate into blood and vasculature cell components. Mesenchymal stem cells (MSC’S) have the capability to differentiate into many different cell types responsible for repair or growth of bone, cartilage, muscle, marrow, tendons, ligaments and connective tissue.
Total Nucleated Cells are a gross indicator of the quality of the bone marrow concentrate product.
Endothelial Progenitor Cells retain the ability to differentiate into other cell types, but to a lesser extent than stem cells. Progenitor cells are capable of releasing BMP-2 and BMP-6, two bone morphogenetic proteins that play a role in bone formation.
Platelets are rich in growth factors, which plays a critical role in the process of stem call differentiation. Growth factors instruct stem cells to differentiate through proteins, which bind to receptors on the surface of the cell. A signal is delivered to the nucleus to turn off or turn on certain genes which generates the proteins that dictate cell differentiation.
Lymphocytes are small white blood cells that play a large role in immune response by protecting the body from disease. Lymphocytes also support the growth of endothelial progenitor cells, which can stimulate angiogenesis, release BMP-2 and BMP-6 and up-regulate the production of BMP-2.
Granulocytes are a type of white blood cells filled with granules that digest microorganisms. Granulocytes release growth factors that support the development of new blood vessels (angiogenesis) necessary to support tissue regeneration and bone formation.
Concentrated BMA delivers a highly concentrated sample of stem cells, progenitor cells and growth factors directly to the application site, harnessing the body’s biologic potential.
• Less risk of immune response
• Higher heterogeneity of stem cells to support tissue regeneration.
• Inexpensive alternative treatment.
These favorable findings have led to the widespread use of PRP treatment for a variety of conditions, including acute and chronic tendon problems, as well as injuries to ligaments and muscles.
The most promising early results have been seen when PRP treatment is used for chronic tendon conditions, such as
lateral epicondylitis (tennis elbow) and Achilles tendinosis, which impacts the Achilles tendon.
In a study involving knee osteoarthritis, PRP treatment was shown to be more effective than hyaluronic acid treatment. PRP has also resulted in positive or similar results when used in the treatment of rotator cuff tears and medial collateral ligament (MCL) injuries in the knee.